MCID: DCT002
MIFTS: 58

Ductal Carcinoma in Situ

Categories: Cancer diseases

Aliases & Classifications for Ductal Carcinoma in Situ

MalaCards integrated aliases for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ 12 30 15 17
Noninfiltrating Intraductal Carcinoma 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0060074
UMLS 74 C0007124

Summaries for Ductal Carcinoma in Situ

Disease Ontology : 12 A breast carcinoma in situ that is characterized by being non-invasive, not having spread outside of the duct into the surrounding breast tissue, has material basis in abnormally proliferating cells, derives from epithelial cells.

MalaCards based summary : Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to comedo carcinoma and in situ carcinoma. An important gene associated with Ductal Carcinoma in Situ is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Doxorubicin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and skin, and related phenotypes are Increased cell death HMECs cells and cellular

Wikipedia : 77 Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...

Related Diseases for Ductal Carcinoma in Situ

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 280)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 33.0 ERBB2 ESR1
2 in situ carcinoma 31.3 BRCA1 CDH1 EGFR ERBB2 ESR1 KRT14
3 breast reconstruction 31.2 BRCA1 BRCA2
4 gynecomastia 30.6 AR CYP19A1 ESR1 PGR
5 mammographic density 30.5 CYP19A1 ESR1 PGR
6 lobular neoplasia 30.3 BRCA1 CDH1 ERBB2 ESR1 MUC1
7 papillary carcinoma 30.2 CDH1 ERBB2 MUC1 PGR
8 breast fibroadenoma 30.1 CYP19A1 ERBB2 ESR1 KRT14 KRT8 PGR
9 bilateral breast cancer 30.1 BRCA1 BRCA2 ERBB2 PGR
10 papilloma 30.0 CCND1 KRT14 KRT5 KRT8 TP53
11 mammary paget's disease 29.9 EGFR ERBB2 ESR1 KRT8 MUC1 PGR
12 breast disease 29.6 BRCA1 BRCA2 CYP19A1 ERBB2 ESR1 KRT5
13 microglandular adenosis 29.5 EGFR ERBB2 PGR PIP TP53
14 breast ductal carcinoma 29.3 AR BRCA1 CCND1 CDH1 EGFR ERBB2
15 adenocarcinoma 29.1 AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
16 squamous cell carcinoma 28.7 AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
17 ovarian cancer 28.5 AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
18 breast cancer 26.7 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
19 breast apocrine carcinoma in situ 11.3
20 intracystic papillary adenoma 10.6 ERBB2 PGR
21 scirrhous adenocarcinoma 10.6 ERBB2 PGR
22 vestibular gland benign neoplasm 10.6 ESR1 PGR
23 vulvar benign neoplasm 10.6 ESR1 PGR
24 breast apocrine carcinoma 10.6 ERBB2 PGR
25 trigonitis 10.6 ESR1 PGR
26 vulvar syringoma 10.6 ESR1 PGR
27 lung leiomyoma 10.6 ESR1 PGR
28 vulvar leiomyoma 10.6 ESR1 PGR
29 bartholin's gland adenoma 10.6 ESR1 PGR
30 gastric papillary adenocarcinoma 10.6 ERBB2 TP53
31 endometrium carcinoma in situ 10.6 PGR TP53
32 breast intraductal proliferative lesion 10.5 EGFR ERBB2
33 rare adenocarcinoma of the breast 10.5 AKT1 TP53
34 breast papillomatosis 10.5 CCND1 ERBB2
35 brain ependymoma 10.5 EGFR TP53
36 protoplasmic astrocytoma 10.5 PTGS2 TP53
37 hereditary site-specific ovarian cancer syndrome 10.5 BRCA1 BRCA2
38 cerebral convexity meningioma 10.5 CDH1 TP53
39 mixed cell type cancer 10.5 ERBB2 PGR TP53
40 adenosarcoma 10.4 ESR1 PGR TP53
41 breast mucoepidermoid carcinoma 10.4 MUC1 PGR
42 supratentorial cancer 10.4 AKT1 EGFR TP53
43 central nervous system cancer 10.4 AKT1 EGFR TP53
44 cerebrum cancer 10.4 AKT1 EGFR TP53
45 glassy cell carcinoma of the cervix 10.4 ERBB2 ESR1 PGR
46 esophagus adenocarcinoma 10.4 ERBB2 PTGS2 TP53
47 barrett's adenocarcinoma 10.4 ERBB2 PTGS2 TP53
48 leukocyte disease 10.4 AKT1 CCND1 TP53
49 penile cancer 10.4 CCND1 EGFR TP53
50 malignant peritoneal mesothelioma 10.4 EGFR MUC1

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:



Diseases related to Ductal Carcinoma in Situ

Symptoms & Phenotypes for Ductal Carcinoma in Situ

GenomeRNAi Phenotypes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.1 BRCA1 EGFR PGR PIP S100A7 TP53

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
2 growth/size/body region MP:0005378 10.48 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
3 digestive/alimentary MP:0005381 10.47 AR BRCA1 BRCA2 CCND1 CDH1 CYP19A1
4 cardiovascular system MP:0005385 10.46 AKT1 AR BRCA1 CCND1 CDH1 CYP19A1
5 endocrine/exocrine gland MP:0005379 10.46 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
6 homeostasis/metabolism MP:0005376 10.46 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
7 hematopoietic system MP:0005397 10.44 AKT1 AR BRCA1 BRCA2 CCND1 CLDN7
8 integument MP:0010771 10.44 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
9 immune system MP:0005387 10.42 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
10 behavior/neurological MP:0005386 10.4 AKT1 AR BRCA1 BRCA2 CCND1 CYP19A1
11 mortality/aging MP:0010768 10.4 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
12 embryo MP:0005380 10.37 AKT1 AR BRCA1 BRCA2 CDH1 EGFR
13 adipose tissue MP:0005375 10.28 AKT1 AR BRCA1 CYP19A1 EGFR ESR1
14 neoplasm MP:0002006 10.27 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
15 limbs/digits/tail MP:0005371 10.18 AR BRCA1 BRCA2 EGFR ERBB2 ESR1
16 muscle MP:0005369 10.18 AKT1 AR BRCA1 CYP19A1 EGFR ERBB2
17 normal MP:0002873 10.18 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
18 nervous system MP:0003631 10.17 AKT1 AR BRCA1 BRCA2 CCND1 CYP19A1
19 craniofacial MP:0005382 10.15 AR CCND1 EGFR ERBB2 KRT14 KRT5
20 liver/biliary system MP:0005370 10.11 AKT1 AR CYP19A1 EGFR ESR1 KRT8
21 reproductive system MP:0005389 10.06 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
22 no phenotypic analysis MP:0003012 9.95 CDH1 EGFR ESR1 KRT5 PGR PTGS2
23 renal/urinary system MP:0005367 9.86 AR BRCA1 CLDN7 CYP19A1 EGFR ESR1
24 pigmentation MP:0001186 9.8 AR BRCA1 CYP19A1 EGFR KRT14 TP53
25 respiratory system MP:0005388 9.61 AKT1 BRCA1 CCND1 EGFR ERBB2 ESR1
26 skeleton MP:0005390 9.4 AKT1 AR BRCA1 BRCA2 CCND1 CYP19A1

Drugs & Therapeutics for Ductal Carcinoma in Situ

Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2 114977-28-5 148124
4
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
5
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
6 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
10 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2
11 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Alkylating Agents Phase 4,Phase 3,Phase 2
13 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
14 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
15
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
16
Tamoxifen Approved Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
17
Sodium Citrate Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
18
Carboplatin Approved Phase 2, Phase 3,Phase 3 41575-94-4 10339178 38904 498142
19
Progesterone Approved, Vet_approved Phase 3,Phase 2,Not Applicable,Early Phase 1 57-83-0 5994
20
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 441203 84093
21
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
22
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
23
leucovorin Approved Phase 3 58-05-9 143 6006
24
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
25
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
26
Exemestane Approved, Investigational Phase 3,Phase 2 107868-30-4 60198
27
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
28
Letrozole Approved, Investigational Phase 3,Phase 2,Not Applicable 112809-51-5 3902
29
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
30
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 33069-62-4 36314
31
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
32
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
33
Pertuzumab Approved Phase 3,Phase 2,Phase 1 380610-27-5, 145040-37-5 2540
34
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
35
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
36
Metformin Approved Phase 3 657-24-9 14219 4091
37
Pembrolizumab Approved Phase 3,Early Phase 1 1374853-91-4
38
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
39
Lenograstim Approved, Investigational Phase 3 135968-09-1
40
Adenosine Approved, Investigational Phase 3 58-61-7 60961
41
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
43
Calcium Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
44
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2,Not Applicable 231277-92-2, 388082-78-8 208908 9941095
45 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Estrogen Receptor Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
48 Steroid Synthesis Inhibitors Phase 3,Phase 2,Not Applicable
49 Citrate Phase 3,Phase 2,Phase 1,Not Applicable
50 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 258)
# Name Status NCT ID Phase Drugs
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
3 An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer Completed NCT01660542 Phase 4 Neoadjuvant Chemotherapy with Docetaxel
4 Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Recruiting NCT02627248 Phase 4 Huaier Granule;Epirubicin;Docetaxel;Cyclophosphamide
5 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Unknown status NCT00321048 Phase 3
6 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
7 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
8 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
9 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
10 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
11 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
12 Study of Docetaxel in Breast Cancer Patients Completed NCT00174707 Phase 3 epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, cyclophosphamide
13 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
14 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed NCT00374322 Phase 3 lapatinib
15 Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer Completed NCT00038467 Phase 3 Tamoxifen;Exemestane
16 Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane Completed NCT00036270 Phase 3 exemestane (Aromasin);tamoxifen + exemestane
17 BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer Completed NCT00528567 Phase 3 Bevacizumab;Standard adjuvant chemotherapy
18 Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer Completed NCT02980965 Phase 3 letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel;fluorouracil, epirubicin, cyclophosphamide, docetaxel
19 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
20 Management of Low-risk DCIS Recruiting NCT02492607 Phase 3
21 CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer Recruiting NCT02918084 Phase 3 Anastrozole or Letrozole or Exemestane;Anastrozole or Letrozole or Exemestane
22 Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer Recruiting NCT03150576 Phase 2, Phase 3 Olaparib;Paclitaxel and Carboplatin
23 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
24 A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients Recruiting NCT03561740 Phase 3 capecitabine
25 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
26 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS) Active, not recruiting NCT00907868 Phase 3
27 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
28 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
29 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
30 APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer Active, not recruiting NCT00402519 Phase 3
31 Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Active, not recruiting NCT01357772 Phase 3 Tamoxifen;placebo
32 Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients Active, not recruiting NCT02772731 Phase 3
33 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Active, not recruiting NCT01358877 Phase 3 5-Fluorouracil;Carboplatin;Cyclophosphamide;Docetaxel;Doxorubicin;Epirubicin;Paclitaxel;Pertuzumab;Placebo;Trastuzumab
34 Oxybutynin Chloride in Managing Hot Flashes Active, not recruiting NCT02961790 Phase 3 Oxybutynin Chloride
35 A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Active, not recruiting NCT01566721 Phase 3 Herceptin
36 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Active, not recruiting NCT03036488 Phase 3 Carboplatin;Paclitaxel;Doxorubicin;Epirubicin;Cyclophosphamide;Placebo
37 Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer Active, not recruiting NCT00878709 Phase 3 neratinib
38 A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer Active, not recruiting NCT01966471 Phase 3 Trastuzumab Emtansine;Trastuzumab;Pertuzumab;Paclitaxel;Epirubicin;Doxorubicin;Docetaxel;Cyclophosphamide;5-Fluorouracil
39 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
40 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
41 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Active, not recruiting NCT01772472 Phase 3 trastuzumab;trastuzumab emtansine
42 Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer Enrolling by invitation NCT03580395 Phase 2, Phase 3 Apatinib;paclitaxel;cisplatin
43 The LightPath® and 68Ga-RM2 in Breast Cancer Study Not yet recruiting NCT03731026 Phase 3 68Ga-RM2
44 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3 risedronate sodium
45 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
46 Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
47 Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer Unknown status NCT01175694 Phase 2
48 Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland Unknown status NCT01630226 Phase 2 Neoadjuvant Cisplatin Chemotherapy
49 Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
50 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel

Search NIH Clinical Center for Ductal Carcinoma in Situ

Genetic Tests for Ductal Carcinoma in Situ

Genetic tests related to Ductal Carcinoma in Situ:

# Genetic test Affiliating Genes
1 Ductal Carcinoma in Situ 30

Anatomical Context for Ductal Carcinoma in Situ

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

42
Breast, Lymph Node, Skin, Prostate, Bone, Testes, Lung

Publications for Ductal Carcinoma in Situ

Articles related to Ductal Carcinoma in Situ:

(show top 50) (show all 2265)
# Title Authors Year
1
Long-term Surveillance of Ductal Carcinoma in Situ Detected with Screening Mammography versus US: Factors Associated with Second Breast Cancer. ( 31038406 )
2019
2
Breast Ductal Carcinoma in Situ: Precursor to Invasive Breast Cancer. ( 31029232 )
2019
3
"Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data" by Hirth JM, Hatch SS, Lin Y, Giordano SH, Silva HC, Kuo Y. ( 30875106 )
2019
4
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. ( 30844755 )
2019
5
Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study. ( 30738200 )
2019
6
Parity Differently Affects the Breast Cancer Specific Survival from Ductal Carcinoma In Situ to Invasive Cancer: A Registry-Based Retrospective Study from Korea. ( 30728717 )
2019
7
Growth Dynamics of Mammographic Calcifications: Differentiating Ductal Carcinoma in Situ from Benign Breast Disease. ( 31112087 )
2019
8
Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ. ( 30273605 )
2019
9
Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ. ( 30385094 )
2019
10
Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. ( 30429518 )
2019
11
Molecular Evaluation of Breast Ductal Carcinoma in Situ with Oncotype DX DCIS. ( 30605628 )
2019
12
Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: Retrospective observational study. ( 30608397 )
2019
13
Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. ( 30653209 )
2019
14
MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ. ( 30659022 )
2019
15
Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma. ( 30712460 )
2019
16
The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ. ( 30725481 )
2019
17
miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway. ( 30989460 )
2019
18
The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. ( 31065110 )
2019
19
A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. ( 31018242 )
2019
20
Survival Outcomes for Women with Ductal Carcinoma in Situ in the Era of Supplemental Screening. ( 31039074 )
2019
21
Intraductal fulvestrant for Therapy of ERα-positive Ductal Carcinoma in Situ (DCIS) of the breast- a Preclinical Study. ( 31046118 )
2019
22
Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. ( 31060593 )
2019
23
Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. ( 31089799 )
2019
24
The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice. ( 31092377 )
2019
25
Predictors of Invasive Breast Cancer in Patients With Ductal Carcinoma In Situ in Ultrasound-Guided Core Needle Biopsy. ( 30069893 )
2019
26
Risk stratification of ductal carcinoma in situ using whole-lesion histogram analysis of the apparent diffusion coefficient. ( 30073498 )
2019
27
Discordant HER2 immunohistochemical expression and gene amplification in ductal carcinoma in situ - evaluating HER2 in synchronous in-situ and invasive carcinoma. ( 30117181 )
2019
28
Accuracy of Breast Magnetic Resonance Imaging Compared to Mammography in the Preoperative Detection and Measurement of Pure Ductal Carcinoma In Situ: A Retrospective Analysis. ( 30149976 )
2019
29
Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS. ( 30190195 )
2019
30
Local Relapse After Breast-Conserving Therapy Versus Mastectomy for Extensive Pure Ductal Carcinoma In Situ ≥4 cm. ( 30253237 )
2019
31
Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing. ( 30284611 )
2019
32
Different Clinical and Pathologic Determinants Might be Possible to Predict Invasive Breast Cancer in Ductal Carcinoma In Situ in Ultrasound-Guided Core Needle Biopsy. ( 30298522 )
2019
33
Comparison of Clinical and Pathologic Characteristics of Ductal Carcinoma in Situ Detected on Mammography versus Ultrasound Only in Asymptomatic Patients. ( 30322671 )
2019
34
The decision to perform or omit sentinel lymph node biopsy during mastectomy for ductal carcinoma in situ should be tailored in accordance with preoperative findings. ( 30328007 )
2019
35
Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. ( 30362065 )
2019
36
Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing. ( 30385093 )
2019
37
Impact of pre-diagnosis depressive symptoms and health-related quality of life on treatment choice for ductal carcinoma in situ and stage I breast cancer in older women. ( 30406869 )
2019
38
In reply to Lambein et al.: 'HER2 protein overexpression in non-amplified ductal carcinoma in situ: quality issue or transcription mechanisms gone awry?' ( 30447011 )
2019
39
Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast. ( 30454971 )
2019
40
Evaluating the frequency of upgrade to malignancy following surgical excision of high-risk breast lesions and ductal carcinoma in situ identified by core needle biopsy. ( 30461129 )
2019
41
Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situ of the breast. ( 30474777 )
2019
42
HER2 protein overexpression in non-amplified ductal carcinoma in situ: quality issue or transcription mechanisms gone awry? ( 30480328 )
2019
43
Leveraging the variable natural history of ductal carcinoma in situ (DCIS) to select optimal therapy. ( 30536119 )
2019
44
Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands. ( 30539380 )
2019
45
Breast conserving surgery with targeted intraoperative radiotherapy for the management of ductal carcinoma in situ. ( 30589080 )
2019
46
No Ink on Ductal Carcinoma In Situ: A Single Centre Experience. ( 30591495 )
2019
47
National consensus recommendations on patient-centered care for ductal carcinoma in situ. ( 30627960 )
2019
48
BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ. ( 30652428 )
2019
49
Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score! ( 30665684 )
2019
50
Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study. ( 30682163 )
2019

Variations for Ductal Carcinoma in Situ

Cosmic variations for Ductal Carcinoma in Situ:

9 (show all 44)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6005476 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2403A>T p.K801N 16:72957743-72957743 0
2 COSM43559 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.517G>T p.V173L 17:7675095-7675095 0
3 COSM10662 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 17:7674220-7674220 0
4 COSM10701 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.824G>T p.C275F 17:7673796-7673796 0
5 COSM10656 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 0
6 COSM10867 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.797G>A p.G266E 17:7673823-7673823 0
7 COSM44415 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 0
8 COSM44737 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.860A>G p.E287G 17:7673760-7673760 0
9 COSM6932 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 0
10 COSM10779 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 17:7673802-7673802 0
11 COSM43714 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.836G>A p.G279E 17:7673784-7673784 0
12 COSM44901 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.532C>G p.H178D 17:7675080-7675080 0
13 COSM10660 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>A p.R273H 17:7673802-7673802 0
14 COSM43814 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 17:7674944-7674944 0
15 COSM11089 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 0
16 COSM6906973 SMARCA4 breast,NS,carcinoma in situ,ductal carcinoma in situ c.1111G>T p.E371* 19:10987917-10987917 0
17 COSM6906974 PPP2R1A breast,NS,carcinoma in situ,ductal carcinoma in situ c.510C>A p.F170L 19:52212692-52212692 0
18 COSM12458 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1634A>C p.E545A 3:179218304-179218304 0
19 COSM775 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>G p.H1047R 3:179234297-179234297 0
20 COSM776 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>T p.H1047L 3:179234297-179234297 0
21 COSM760 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1624G>A p.E542K 3:179218294-179218294 0
22 COSM763 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1633G>A p.E545K 3:179218303-179218303 0
23 COSM774 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3139C>T p.H1047Y 3:179234296-179234296 0
24 COSM754 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1035T>A p.N345K 3:179203765-179203765 0
25 COSM580 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.181C>A p.Q61K 1:114713909-114713909 0
26 COSM565 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>C p.G12A 1:114716126-114716126 0
27 COSM6057047 NOTCH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.7372C>T p.P2458S 9:136496367-136496367 0
28 COSM6005481 MAP2K2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.931G>T p.D311Y 19:4097332-4097332 0
29 COSM521 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>A p.G12D 12:25245350-25245350 0
30 COSM516 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.34G>T p.G12C 12:25245351-25245351 0
31 COSM532 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.38G>A p.G13D 12:25245347-25245347 0
32 COSM520 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>T p.G12V 12:25245350-25245350 0
33 COSM1179671 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.925C>T p.P309S 7:152273792-152273792 0
34 COSM4595028 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.2681G>A p.R894Q 7:152235905-152235905 0
35 COSM6057048 HRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.148A>G p.T50A 11:533908-533908 0
36 COSM6906971 H3F3A breast,NS,carcinoma in situ,ductal carcinoma in situ c.218G>A p.R73Q 1:226065745-226065745 0
37 COSM48358 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.929C>T p.S310F 17:39711955-39711955 0
38 COSM14060 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2264T>C p.L755S 17:39723967-39723967 0
39 COSM19786 CDH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.779C>T p.P260L 16:68810288-68810288 0
40 COSM6057049 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.61A>G p.T21A 14:104780202-104780202 0
41 COSM33765 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.49G>A p.E17K 14:104780214-104780214 0
42 COSM5174142 breast,NS,carcinoma in situ,ductal carcinoma in situ c.884C>T p.S295F 17:39711955-39711955 0
43 COSM6906972 breast,NS,carcinoma in situ,ductal carcinoma in situ c.1111G>T p.E371* 19:10987917-10987917 0
44 COSM6964823 breast,NS,carcinoma in situ,ductal carcinoma in situ c.659C>T p.T220M 1:39897898-39897898 0

Expression for Ductal Carcinoma in Situ

Search GEO for disease gene expression data for Ductal Carcinoma in Situ.

Pathways for Ductal Carcinoma in Situ

Pathways related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 AKT1 BRCA1 CCND1 CDH1 EGFR ERBB2
2
Show member pathways
13.76 AKT1 BRCA1 BRCA2 CCND1 EGFR ERBB2
3
Show member pathways
13.39 AKT1 CCND1 EGFR ERBB2 MUC1 PTGS2
4
Show member pathways
13.01 AKT1 BRCA1 CCND1 EGFR ERBB2 PTGS2
5
Show member pathways
12.8 AKT1 AR BRCA2 CCND1 CDH1 EGFR
6
Show member pathways
12.75 AKT1 CDH1 ERBB2 ESR1 PTGS2 TP53
7
Show member pathways
12.73 BRCA1 BRCA2 CCND1 ESR1 TP53
8
Show member pathways
12.63 AKT1 CCND1 EGFR ERBB2 TP53
9 12.58 AKT1 AR BRCA2 CCND1 CDH1 EGFR
10 12.51 BRCA1 CCND1 EGFR ERBB2 PTGS2 TP53
11
Show member pathways
12.51 AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
12 12.47 AKT1 CCND1 CDH1 PTGS2 TP53
13
Show member pathways
12.46 AKT1 EGFR ERBB2 TP53
14
Show member pathways
12.46 AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
15
Show member pathways
12.43 AKT1 BRCA1 ESR1 PTGS2
16
Show member pathways
12.33 AKT1 CCND1 EGFR ERBB2 ESR1 PTGS2
17
Show member pathways
12.32 AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
18
Show member pathways
12.29 AKT1 BRCA1 CCND1 TP53
19
Show member pathways
12.26 BRCA1 CCND1 ESR1 PGR
20 12.26 AKT1 CCND1 EGFR ERBB2 ESR1 TP53
21
Show member pathways
12.23 AKT1 CCND1 EGFR ERBB2 TP53
22 12.16 AKT1 CCND1 EGFR ERBB2 TP53
23
Show member pathways
12.13 AKT1 AR CCND1 EGFR ERBB2
24
Show member pathways
12.11 AKT1 CCND1 EGFR ERBB2
25
Show member pathways
12.08 AKT1 EGFR ERBB2 TP53
26 12.06 CCND1 EGFR PTGS2 TP53
27 12.06 AKT1 CCND1 CDH1 EGFR PTGS2 TP53
28
Show member pathways
12.03 AKT1 CCND1 CDH1 PTGS2 TP53
29 12.03 AKT1 CCND1 ESR1 TP53
30 12.02 AKT1 CCND1 ERBB2 TP53
31 12 AKT1 CCND1 EGFR TP53
32 12 AKT1 CCND1 MUC1 PTGS2 TP53
33
Show member pathways
11.98 EGFR ERBB2 ESR1 PGR
34 11.91 AKT1 CCND1 PTGS2 TP53
35
Show member pathways
11.87 AR ESR1 PGR
36 11.85 AKT1 AR BRCA1 CCND1 EGFR
37 11.84 AKT1 KRT14 KRT5 TP53
38
Show member pathways
11.83 BRCA1 BRCA2 TP53
39 11.81 AR CCND1 CDH1
40 11.79 AKT1 AR ESR1
41 11.78 AKT1 BRCA1 ERBB2 TP53
42 11.76 CDH1 EGFR ERBB2
43
Show member pathways
11.75 CCND1 EGFR ESR1
44 11.73 AKT1 EGFR ERBB2
45 11.73 AKT1 BRCA1 ERBB2 TP53
46 11.72 AKT1 CCND1 EGFR ESR1
47 11.71 AKT1 EGFR ERBB2 TP53
48
Show member pathways
11.67 AKT1 CCND1 EGFR ERBB2
49 11.67 BRCA1 CCND1 ERBB2 S100A7
50 11.67 CCND1 CDH1 EGFR ERBB2 TP53

GO Terms for Ductal Carcinoma in Situ

Cellular components related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.89 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
2 nuclear chromatin GO:0000790 9.56 AR ESR1 MUC1 TP53
3 protein-containing complex GO:0032991 9.23 AKT1 AR BRCA1 BRCA2 EGFR ESR1
4 nucleus GO:0005634 10.06 AKT1 AR BRCA1 BRCA2 CCND1 EGFR

Biological processes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 protein deubiquitination GO:0016579 9.97 AR BRCA1 ESR1 TP53
2 positive regulation of protein phosphorylation GO:0001934 9.9 AKT1 CCND1 EGFR ERBB2
3 cytokine-mediated signaling pathway GO:0019221 9.89 AKT1 CCND1 MUC1 PTGS2 TP53
4 transcription initiation from RNA polymerase II promoter GO:0006367 9.88 AR CCND1 ESR1 PGR
5 positive regulation of gene expression GO:0010628 9.88 AKT1 AR BRCA1 ERBB2 PIP TP53
6 cell proliferation GO:0008283 9.85 AKT1 AR BRCA2 EGFR ERBB2 TP53
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 AKT1 EGFR PTGS2
8 positive regulation of cell growth GO:0030307 9.84 AKT1 EGFR ERBB2
9 cellular response to mechanical stimulus GO:0071260 9.82 AKT1 EGFR PTGS2
10 response to estrogen GO:0043627 9.81 BRCA1 CCND1 ESR1
11 cellular response to growth factor stimulus GO:0071363 9.79 AKT1 EGFR ERBB2
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.78 AKT1 EGFR PTGS2
13 steroid hormone mediated signaling pathway GO:0043401 9.76 AR ESR1 PGR
14 epidermis development GO:0008544 9.76 EGFR KRT14 KRT5 S100A7
15 positive regulation of transcription, DNA-templated GO:0045893 9.76 AKT1 AR BRCA1 BRCA2 CDH1 EGFR
16 cellular response to epidermal growth factor stimulus GO:0071364 9.73 AKT1 EGFR ERBB2
17 response to organic substance GO:0010033 9.73 AKT1 CCND1 CDH1 PTGS2
18 hemidesmosome assembly GO:0031581 9.67 KRT14 KRT5
19 Leydig cell differentiation GO:0033327 9.66 AR CCND1
20 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.65 ESR1 TP53
21 positive regulation of vasoconstriction GO:0045907 9.65 AKT1 EGFR PTGS2
22 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.64 EGFR TP53
23 mitotic G1 DNA damage checkpoint GO:0031571 9.63 CCND1 TP53
24 prostate gland growth GO:0060736 9.62 AR CYP19A1
25 negative regulation of ERBB signaling pathway GO:1901185 9.59 EGFR ERBB2
26 cellular response to indole-3-methanol GO:0071681 9.57 BRCA1 CDH1
27 response to estradiol GO:0032355 9.56 CCND1 EGFR ESR1 PTGS2
28 chordate embryonic development GO:0043009 9.55 BRCA1 BRCA2
29 morphogenesis of an epithelial fold GO:0060571 9.54 AR EGFR
30 mammary gland development GO:0030879 9.52 CYP19A1 PGR
31 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.51 AR PGR
32 mammary gland alveolus development GO:0060749 9.5 AR CCND1 ESR1
33 positive regulation of transcription by RNA polymerase III GO:0045945 9.35 AR
34 response to UV-A GO:0070141 9.13 AKT1 CCND1 EGFR
35 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.92 BRCA1 BRCA2 MUC1 TP53
36 positive regulation of transcription by RNA polymerase II GO:0045944 10.17 AKT1 AR BRCA1 EGFR ESR1 PGR
37 cellular response to DNA damage stimulus GO:0006974 10.04 AKT1 BRCA1 BRCA2 CCND1 TP53

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.95 AR BRCA1 ESR1 PGR S100A7 TP53
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.85 AR ESR1 MUC1 PGR TP53
3 protein kinase binding GO:0019901 9.83 AKT1 CCND1 EGFR ESR1 TP53
4 beta-catenin binding GO:0008013 9.7 AR CDH1 ESR1
5 protein phosphatase binding GO:0019903 9.69 EGFR ERBB2 TP53
6 ATPase binding GO:0051117 9.67 AR ESR1 PGR
7 identical protein binding GO:0042802 9.65 AKT1 BRCA1 BRCA2 CDH1 CLDN7 EGFR
8 steroid hormone receptor activity GO:0003707 9.58 AR ESR1 PGR
9 nuclear receptor activity GO:0004879 9.54 AR ESR1 PGR
10 steroid binding GO:0005496 9.5 AR ESR1 PGR
11 nitric-oxide synthase regulator activity GO:0030235 9.33 AKT1 EGFR ESR1
12 enzyme binding GO:0019899 9.28 AKT1 AR BRCA1 CCND1 EGFR ESR1
13 protein binding GO:0005515 10.23 AKT1 AR BRCA1 BRCA2 CCND1 CDH1

Sources for Ductal Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....